Provided by Tiger Fintech (Singapore) Pte. Ltd.

Oculis

18.74
-0.2300-1.21%
Post-market: 19.220.4800+2.56%17:38 EDT
Volume:39.13K
Turnover:731.28K
Market Cap:879.75M
PE:-8.00
High:18.99
Open:18.96
Low:18.30
Close:18.97
Loading ...

Company Profile

Company Name:
Oculis
Exchange:
NASDAQ
Establishment Date:
- -
Employees:
49
Office Location:
Bahnhofstrasse 7,Zug,Zug,Switzerland
Zip Code:
6300
Fax:
- -
Introduction:
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops novel topical treatments for ophthalmic diseases for both back- and front-of-the-eye. The company's lead candidate is OCS-01, a topical dexamethasone formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for keratoconjunctivitis sicca, or dry eye disease; and OCS-05, a novel neuroprotective agent for acute optic neuritis and other neuro-ophtha disorders, such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The company is based in Zug, Switzerland.